Facility Qualification Protocol

Facility Qualification is a documented process used to confirm that pharmaceutical manufacturing, packaging, storage, microbiological testing, and supporting areas are properly designed, installed, operated, and maintained according to approved specifications and cGMP requirements. The qualification begins with User Requirement Specification (URS), which defines the intended use, design needs, and performance expectations of the facility. Design Qualification (DQ) verifies that the proposed design meets these requirements. Installation Qualification (IQ) confirms that the facility, utilities, materials, instruments, drawings, and related systems are installed according to approved designs and documents. Operational Qualification (OQ) demonstrates that critical facility parameters function correctly throughout specified operating ranges, with trained personnel and calibrated instruments. Performance Qualification (PQ) provides documented evidence that the facility consistently performs effectively under routine working conditions. The protocol also includes responsibilities, supporting documents, attachments, deviations, recommendations, conclusions, and formal review and approval by concerned departments and quality management before routine pharmaceutical operations begin.

IMPACT ASSESSMENT

Facility qualification has a direct impact on product quality, patient safety, and smooth pharmaceutical operations. It confirms that manufacturing, packaging, storage, microbiology, and support areas are properly designed, installed, and working as intended. If the facility is not qualified, problems such as wrong temperature, poor air flow, contamination, equipment malfunction, or unsafe working conditions may affect the product. The qualification process checks user requirements, design, installation, operation, and performance before routine use. It also ensures that instruments are calibrated, staff are trained, documents are available, and any deviations are reviewed and corrected. Proper qualification reduces the risk of errors, contamination, product rejection, regulatory observations, and production delays. It provides documented evidence that the facility can consistently support safe and reliable manufacturing. Therefore, successful qualification gives confidence that the area is suitable for its intended purpose and meets company, quality, and cGMP requirements during normal operation throughout its planned operating life cycle.

Facility Qualification – Questions & Answers

Q1. What is Facility Qualification in the pharmaceutical industry?
Answer: Facility Qualification is a documented and systematic process used to demonstrate that pharmaceutical premises, manufacturing areas, laboratories, storage areas, utilities, and associated systems are appropriately designed, installed, operated, and maintained for their intended purpose. WHO specifically states that premises, systems, utilities, and equipment should be appropriately designed, installed, qualified, operated, cleaned, and maintained throughout their lifecycle.

Q2. What are the main stages of Facility Qualification?
Answer: The typical qualification lifecycle consists of URS → DQ → IQ → OQ → PQ. The URS defines what the facility and its systems must achieve; DQ confirms that the proposed design meets the URS and GMP expectations; IQ verifies correct installation; OQ demonstrates operation within defined ranges; and PQ confirms consistent performance under routine operating conditions. WHO specifically identifies URS, DQ, IQ, OQ, and PQ as qualification stages for new premises, systems, utilities, and equipment.

Q3. Why must Facility Qualification be completed before routine pharmaceutical operations?
Answer: Qualification provides documented evidence that the facility and its critical utilities can consistently support product quality, prevent contamination and cross-contamination, maintain required environmental conditions, and operate according to predefined specifications. Qualification should be performed according to approved protocols containing predetermined tests and acceptance criteria, with results documented in qualification reports.

Reference Guidelines

1. EU GMP – EudraLex Volume 4, Annex 15: Qualification and Validation
   This is one of the primary references for the qualification lifecycle and applies to facilities, equipment, utilities, and processes. The European Commission currently lists Annex 15 as the applicable EU GMP qualification and validation annex.
2. EU GMP – EudraLex Volume 4, Part I, Chapter 3: Premises and Equipment
   Provides GMP expectations for the location, design, construction, maintenance, and suitability of pharmaceutical premises and equipment.
3. WHO Technical Report Series No. 1019, Annex 3 – GMP: Guidelines on Validation, Appendix 6: Guidelines on Qualification
   Covers qualification of premises, systems, utilities and equipment and specifically describes URS, DQ, IQ, OQ and PQ.
4. US FDA – 21 CFR Parts 210 and 211, Current Good Manufacturing Practice
   Particularly relevant are 21 CFR Part 211 Subpart C – Buildings and Facilities, including requirements concerning facility design, HVAC/air handling, sanitation and contamination control. FDA states that CGMP regulations establish minimum requirements for facilities and controls used in drug manufacturing, processing and packing.
5. EU GMP Annex 1 – Manufacture of Sterile Medicinal Products
   Applicable when the facility includes sterile manufacturing, aseptic processing, cleanrooms or clean-air equipment. The current Annex 1 is fully applicable in the EU.